Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niall M B Martin

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Cancer Research|August 24, 2016
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical ModelsLenka Oplustil O'Connor, Stuart L Rulten, Aaron N Cranston, et al.
Molecular Cancer Therapeutics|May 12, 2012
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3KJoanne M Munck, Michael A Batey, Yan Zhao, et al.
Journal of Medicinal Chemistry|September 20, 2008
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1Keith A Menear, Claire Adcock, Robert Boulter, et al.
Journal of Medicinal Chemistry|March 21, 2007
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinaseJonathan J Hollick, Laurent J M Rigoreau, Celine Cano-Soumillac, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacyHelen M R Robinson, Vera Grinkevich, Jayesh B Majithiya, et al.
Nature Communications|June 18, 2021
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistanceDiana Zatreanu, Helen M R Robinson, Omar Alkhatib, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Cancer Research|August 24, 2016
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical ModelsLenka Oplustil O'Connor, Stuart L Rulten, Aaron N Cranston, et al.
Molecular Cancer Therapeutics|May 12, 2012
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3KJoanne M Munck, Michael A Batey, Yan Zhao, et al.
Journal of Medicinal Chemistry|September 20, 2008
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1Keith A Menear, Claire Adcock, Robert Boulter, et al.
Journal of Medicinal Chemistry|March 21, 2007
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinaseJonathan J Hollick, Laurent J M Rigoreau, Celine Cano-Soumillac, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacyHelen M R Robinson, Vera Grinkevich, Jayesh B Majithiya, et al.
Nature Communications|June 18, 2021
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistanceDiana Zatreanu, Helen M R Robinson, Omar Alkhatib, et al.
Pageof 3